Bone Index, a Finland-based medical technology company specializing in bone diagnostics, has announced the successful completion of a new financing round, with the exact amount remaining undisclosed. The round was spearheaded by Lynx Financial, a Shanghai-based fund with a dedicated focus on healthcare and life sciences, and was supported by contributions from existing investors. The capital raised will be strategically directed towards scaling up the company’s manufacturing capabilities and enhancing market promotion efforts, in response to the escalating demand for bone diagnostic products across North America and the Asia-Pacific region. In tandem with this investment, Bone Index has forged a partnership with Lynx Financial to expand the reach of its innovative technologies and products in these key markets.
The company’s flagship product, the Bindex system, stands at the forefront of osteoporosis diagnosis, offering rapid and precise results. Utilizing proprietary algorithms, Bindex is capable of accurately gauging hip bone density by analyzing the cortical bone thickness in the tibia. In multiple clinical trials, Bindex has demonstrated up to a 90% consistency with the dual energy X-ray absorptiometry (DXA), the gold standard for bone density measurement. The Bindex system is a compact, handheld device designed for versatility in both early screening and hospital-based diagnostic examinations, with the potential to significantly alleviate the medical burden associated with osteoporosis detection.- Flcube.com
